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for Neonatal InfantsPatients with chronic kidney diseases (CKD) have been
classified into stages 1e5 according to their serum
creatinine-based estimated glomerular filtration rate
(eGFR) for over three decades. Recently, cystatin C was
proposed as an alternative filtration marker for creatinine
due to limitations of creatinine measurement in risk
prediction, particularly in patients with reduced muscle
mass.1 Cystatin C is a non-glycosylated, low molecular
weight, cation protein that is regularly synthesized by
most nucleated cells. Due to its low molecular weight and
positive charge at physiological pH, it is freely filtered by
the glomerulus and then reabsorbed and catabolized by
proximal tubular cells. Urinary concentration of cystatin
C is very low under normal conditions, and it is not
affected by muscular mass, nutritional status, age, or
body size. Additionally, creatinine has a variable renal
tubular secretion and reabsorption, whereas cystatin C
has no renal tubular secretion.2 A major meta-analysis
study covering 11 general population-based studies and
five CKD cohorts (with a total of 93,710 participants)
suggested that using cystatin C alone or in combination
with creatinine for eGFR calculation significantly
improved the risk classification for death, cardiovascular
diseases, and end-stage renal disease across diverse
populations.3
Studies on pediatric patients showed that cystatin C-
based equations were more accurate for estimating GFR
when compared with serum creatinine-based GFR equa-
tions.4 Cystatin C is also a more accurate marker for GFR
estimation in pediatric patients with acute kidney injury
(AKI). Elevation of cystatin C occurs before elevation of
serum creatinine; therefore, cystatin C can be used as a
preferable marker for early detection of AKI, as well as in
future AKI outcome studies and clinical trials. In children
undergoing cardiac surgery, cystatin C was more strongly
associated with interleukin-18 and kidney injury molecule-1
biomarkers of AKI than was serum creatinine.5 Recent
studies also demonstrated that cystatin C was a better
marker for GFR estimation in preterm infants with birth
body weights <1500 g.6http://dx.doi.org/10.1016/j.pedneo.2016.03.001
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-ndA study by Kim et al7 went one step further to correlate
cystatin C-based eGFR with transient tachypnea of the
newborn (TTNB).7 They demonstrated that shorter
tachypnea duration and hospital stay were correlated with
higher cystatin C-based eGFR. Their data suggested an as-
sociation between newborn renal function and TTNB-
symptom duration.7 Although an association between cys-
tatin C and chronic obstructive pulmonary disease was re-
ported in adult populations, no prior studies on neonates
were ever conducted. This study demonstrated a significant
association between symptom duration and cystatin C, but
not with urine output, and suggested that the degree of
organ maturation is a more important factor for consider-
ation. Additionally, the authors proposed that epithelial
sodium channels (ENaCs) and sodiumepotassium adenosine
triphosphatase (Na/K-ATPase), molecules essential for fluid
management, may be the shared linkages between the
lungs and kidneys while monitoring organ maturation.
Further mechanistic and in vivo studies involving both
ENaCs and Na/K-ATPase molecules are required, and
further clinical studies using cystatin C as a better marker
to improve pediatric patient care and management should
be encouraged.
Ching-Feng Cheng*
Department of Pediatrics, Tzu Chi General Hospital and
Tzu Chi University, Hualien, Taiwan
* Corresponding author. Department of Pediatrics, Tzu Chi
General Hospital and Tzu Chi University, 707, Chung-Yang
Road, Section 3, Hualien 970, Taiwan.
E-mail address: chengcf@mail.tcu.edu.tw
Mar 1, 2016
References
1. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC,
Matsushita K, et al. The definition, classification, and prognosisby Elsevier Taiwan LLC. This is an open access article under the
/4.0/).
164 Editorialof chronic kidney disease: a KDIGO Controversies conference
report. Kidney Int 2011;80:17e28.
2. Grubb AO. Cystatin C d properties and use as diagnostic
marker. Adv Clin Chem 2000;35:63e99.
3. Shlipak MG, Matsushita K, A¨rnlo¨v J, Inker LA, Katz R,
Polkinghorne KR, et al. Cystatin C versus creatinine in deter-
mining risk based on kidney function. N Engl J Med 2013;369:
932e43.
4. Ataei N, Bazargani B, Ameli S, Madani A, Javadilarijani F,
Moghtaderi M, et al. Early detection of acute kidney injury by
serum cystatin C in critically ill children. Pediatr Nephrol 2014;
29:133e8.
5. Zappitelli M, Greenberg JH, Coca SG, Krawczeski CD, Li S,
Thiessen-Philbrook HR, et al. Association of definition of acutekidney injury by cystatin C rise with biomarkers and clinical
outcomes in children undergoing cardiac surgery. JAMA Pediatr
2015;169:583e91.
6. Bardallo Cruzado L, Pe´rez Gonza´lez E, Martı´nez Martos Z, Ber-
mudo Guitarte C, Granero Asencio M, Luna Lagares S, et al.
Serum cystatin C levels in preterm newborns in our setting:
Correlation with serum creatinine and preterm pathologies.
Nefrologia 2015;35:296e303 [Article in English, Spanish].
7. Kim BB, Chung SH, Yoon HS, Hahn WH, Bae CW, Choi YS.
Decreased Cystatin CeEstimated Glomerular Filtration Rate Is
Correlated with Prolonged Hospital Stay in Transient Tachypnea
of Newborn Infants. Pediatr Neonatol 2016;57:195e200.
